The company can again ship the Duchenne gene therapy for patients who can still walk, following a one-week pause triggered by ...

In a major win for Sarepta Therapeutics Inc., US regulators are recommending that patients who can walk be allowed to take ...

The FDA has partially reversed course on its push to halt shipments of a controversial gene therapy made by Sarepta ...